---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-048621"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2021-09-23T23:59:59+00:00"
generated_at: "2026-06-29T01:49:16.258406+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera: EU Joint Procurement for up to 220,000 doses of bamlanivimab/etesevimab

## Summary
- EC and Lilly agree to supply up to 220,000 doses of bamlanivimab plus etesevimab for COVID-19 in EU/EEA patients 12+ at risk.
- Therapy neutralizes Delta variant causing >95% of new EU/EEA infections.
- In US, therapy treated >535,000 patients; estimated 25,000 hospitalizations and 10,000 lives saved.
- Participating EU/EEA countries can purchase directly from Lilly after national or EU authorization.

## SEC filing metadata
- accession: 0001564590-21-048621
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2021-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459021048621/0001564590-21-048621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459021048621/abcl-8k_20210921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-048621
- JSON: https://secwatch.observer/filing/0001564590-21-048621.json
- Plain text: https://secwatch.observer/filing/0001564590-21-048621.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.